Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 12; 185(6):1146-1159.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Double-Blind Method
Humans
Psoriasis
Quality of Life
Severity of Illness Index
Treatment Outcome

authors with profiles

Kenneth Gordon